Efficacy and safety of spesolimab for the treatment of generalized pustular psoriasis flares in hospitalized versus non-hospitalized patients

Generalized pustular psoriasis (GPP) is a rare skin disease associated with excess hospital admissions. In Effisayil 1 (NCT03782792), spesolimab treatment led to rapid pustular and skin clearance, with a favorable safety profile, in patients with GPP flares. We report the efficacy and safety of spesolimab in hospitalized and non-hospitalized patients. Overall, 51/53 patients in Effisayil 1 had hospitalization data: 25 (spesolimab, 17; placebo, 8) were hospitalized due to a GPP flare at randomization (median length of stay, 8.0 days); 26 were not hospitalized (spesolimab, 16; placebo, 10). Baseline demographics were similar between spesolimab and placebo treatment groups independent of hospitalization status.